3-(4-tert-butylphenyl)glutaric diacid | 185049-53-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(4-tert-butylphenyl)glutaric diacid
• 英文别名: 3-(4-tert-butylphenyl)glutaric acid；3-(4-Tert-butylphenyl)pentanedioic acid
• CAS: 185049-53-0
• 化学式: C₁₅H₂₀O₄
• 分子量: 264.321
• InChiKey: FAWGALXOOXRDHE-UHFFFAOYSA-N

物化性质

• 沸点：
  399.5±27.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-tert-butylphenyl)glutaric diacid 在 1-[3-(diethylamino)propyl]-3-ethylcarbodiimide hydrochloride 、 乙酸酐 、 对甲苯磺酸 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 2-[[3-(4-tert-butylphenyl)-5-[[(3S,5S,8R,9S,10S,13S,14S,17S)-17-[3-(4-tert-butylphenyl)-5-oxo-5-(2-sulfoethylamino)pentanoyl]oxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-5-oxopentanoyl]amino]ethanesulfonic acid
  参考文献：
  名称：

  人工细胞色素p-450酶催化甾体底物的氧化。

  摘要：

  包含带有环糊精结合基团的锰-卟啉的催化剂能够以底物选择性，区域和立体选择性以及高催化转化率进行羟基化。催化剂/底物配合物的几何形状超越了固有的底物反应性，从而允许在存在仲甲醇基团和碳-碳双键的情况下，如在酶促反应中，攻击类固醇的几何可及的饱和碳。甾族碳9位的选择性羟基化特别实用。

  DOI：

  10.1021/jo020174u
• 作为产物：
  描述：

  对叔丁基苯甲醛 在 哌啶 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 22.0h， 生成 3-(4-tert-butylphenyl)glutaric diacid
  参考文献：
  名称：

  4-Benzimidazolyl-3-Phenylbutanoic Acids As Novel Pif-Pocket-Targeting Allosteric Inhibitors of Protein Kinase PKCζ

  摘要：

  Protein kinase inhibitors with an allosteric mode of action are expected to reach, in many cases, higher selectivity for the target enzyme than ATP-competitive compounds. Therefore, basic research is aiming at identifying and establishing novel sites on the catalytic domain of protein kinases which might be targeted by allosteric inhibitors. We previously published the first structure-activity relationships (SARs) for allosteric activators of protein kinase PDK1. Here, we present the design, synthesis, and SAR data on a series of novel compounds, 4-benzimidazolyl-3-phenylbutanoic acids, that inhibit the atypical protein kinace C (PKC) zeta via binding to the PIF-pocket. Key positions were identified in the compounds that can be modified to increase potency and selectivity. Some congeners showed a high selectivity toward PKC zeta, lacking inhibition of the most closely related isoform, PKCl, and of further AGC kinases. Furthermore, evidence is provided that these compounds are also active toward cellular PKC zeta without loss of potency compared to the cell-free assay.

  DOI：

  10.1021/jm2005892

文献信息

• [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
  申请人：UNIV SAARLAND

  公开号：WO2010043711A1

  公开（公告）日：2010-04-22

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  该发明提供特定的小分子化合物，这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用，提供这些化合物的制备方法，包含这些化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• ALLOSTERIC PROTEIN KINASE MODULATORS
  申请人：Engel Matthias

  公开号：US20120046307A1

  公开（公告）日：2012-02-23

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了特定的小分子化合物，它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用，其生产方法，包含该化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• Switchable divergent di- or tricarboxylation of allylic alcohols with CO2
  作者：Bo Yu、Yi Liu、Han-Zhi Xiao、Shu-Rong Zhang、Chuan-Kun Ran、Lei Song、Yuan-Xu Jiang、Chang-Fu Li、Jian-Heng Ye、Da-Gang Yu

  DOI：10.1016/j.chempr.2023.12.005

  日期：2024.3

  Visible-light-driven switchable divergent di- or tricarboxylation of allylic alcohols with CO is realized to selectively upgrade multiple CO units to polycarboxylic acids. The derivatization of corresponding polycarboxylic acids could deliver the potential functional materials in luminescence and biomaterials.

  实现了烯丙醇与CO的可见光驱动可切换发散二羧化或三羧化，选择性地将多个CO单元升级为多元羧酸。相应的聚羧酸的衍生化可以在发光和生物材料中提供潜在的功能材料。
• Divergent defluorocarboxylation of α-CF3 alkenes with formate via photocatalyzed selective mono- or triple C-F bond cleavage
  作者：Xing-Yu Wang、Pei Xu、Wen-Wen Liu、Hao-Qiang Jiang、Song-Lei Zhu、Dong Guo、Xu Zhu

  DOI：10.1007/s11426-023-1731-x

  日期：2024.1

  Unprecedented divergent synthesis of gem-difluorovinylacetic acid and glutaric acid derivatives from α-CF3 alkenes with formate as the carbonyl source was disclosed. The reaction can undergo selective mono- or triple C-F bond cleavage by simply switching the photocatalyst and hydrogen atom transfer (HAT) catalyst under visible-light-induced conditions at room temperature. Foramte acts as both the C1

  公开了以甲酸盐作为羰基源，从α -CF 3烯烃前所未有地不同合成偕二氟乙烯基乙酸和戊二酸衍生物。通过在室温下可见光诱导条件下简单地切换光催化剂和氢原子转移（HAT）催化剂，该反应可以选择性地发生单碳或三碳键断裂。Foramte 通过生成 CO 2 •−物质充当 C1 源和还原剂，CO 2 •− 物质经过吉斯自由基加成到缺电子烯烃上，触发连续的 CF 键断裂和羧化过程。
• Allosteric protein kinase modulators
  申请人：Universität des Saarlandes

  公开号：EP2177510A1

  公开（公告）日：2010-04-21

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了可异位调节 AGC 蛋白激酶和 Aurora 家族蛋白激酶活性或调节蛋白-蛋白相互作用的特异性小分子化合物、其生产方法、包含这些化合物的药物组合物，以及它们用于制备治疗和预防与 AGC 蛋白激酶或 Aurora 家族蛋白激酶异常活性相关疾病的药物的用途。